Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They presently have a $116.00 price target on the biopharmaceutical company's stock. Cantor Fitzgerald's price target would indicate a potential upside of 129.61% from the stock's current price.

Other research analysts also recently issued reports about the stock. TD Cowen boosted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Royal Bank of Canada reiterated an "outperform" rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Thursday, September 26th. Canaccord Genuity Group restated a "buy" rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. Wedbush boosted their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a "neutral" rating in a research report on Friday, August 2nd. Finally, The Goldman Sachs Group lifted their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $86.69.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE traded down $1.66 during trading on Wednesday, reaching $50.52. The company's stock had a trading volume of 1,611,796 shares, compared to its average volume of 781,603. The stock has a market capitalization of $4.66 billion, a PE ratio of -6.98 and a beta of 0.58. The firm has a fifty day moving average of $55.47 and a 200 day moving average of $48.09. Ultragenyx Pharmaceutical has a one year low of $34.06 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analysts' expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm's revenue was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.23) earnings per share. Research analysts expect that Ultragenyx Pharmaceutical will post -6.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of the company's stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO Howard Horn sold 7,465 shares of the company's stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares of the company's stock, valued at approximately $124,209,562.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,556 shares of company stock valued at $1,515,967. Corporate insiders own 5.80% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 67.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock valued at $155,000 after purchasing an additional 1,339 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at about $227,000. GSA Capital Partners LLP purchased a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $493,000. Duality Advisers LP grew its stake in shares of Ultragenyx Pharmaceutical by 1.5% in the first quarter. Duality Advisers LP now owns 39,977 shares of the biopharmaceutical company's stock worth $1,867,000 after acquiring an additional 606 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 3.0% during the first quarter. Swiss National Bank now owns 145,852 shares of the biopharmaceutical company's stock valued at $6,810,000 after purchasing an additional 4,300 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.